Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent B-Cell Non-Hodgkin's Lymphomas”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT01263418
What this trial is testing

Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas

Who this might be right for
Lymphoma, Non-HodgkinLymphoma, FollicularLymphoma, B-Cell, Marginal Zone+2 more
UNC Lineberger Comprehensive Cancer Center
Not applicableLooking for participantsNCT05876923
What this trial is testing

The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients

Who this might be right for
Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaIndolent Non-hodgkin Lymphoma
Mayo Clinic 70
Early research (Phase 1)Active Not RecruitingNCT04464200
What this trial is testing

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Who this might be right for
Diffuse Large B Cell LymphomaPrimary Mediastinal Large B Cell LymphomaTransformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma+6 more
Memorial Sloan Kettering Cancer Center 30
Early research (Phase 1)UnknownNCT05020639
What this trial is testing

TQB3820 in Patients With Hematological Malignancies

Who this might be right for
Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 116
Testing effectiveness (Phase 2)Study completedNCT02342665
What this trial is testing

Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Who this might be right for
Lymphoma Non-Hodgkin
Bayer 25
Testing effectiveness (Phase 2)Study completedNCT01994382
What this trial is testing

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Who this might be right for
Follicular Lymphoma (FL/Indolent NHL)Aggressive NHL (a NHL)Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)+2 more
Alexion Pharmaceuticals, Inc. 260
Testing effectiveness (Phase 2)Study completedNCT00093769
What this trial is testing

Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Jonsson Comprehensive Cancer Center 15
Early research (Phase 1)Looking for participantsNCT05755087
What this trial is testing

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell TypeRecurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements+6 more
Lapo Alinari
Large-scale testing (Phase 3)Study completedNCT01231412
What this trial is testing

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAggressive Non-Hodgkin Lymphoma+16 more
Fred Hutchinson Cancer Center 174
Early research (Phase 1)Study completedNCT04578600
What this trial is testing

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Who this might be right for
Indolent B-Cell Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic Leukemia+16 more
Joseph Tuscano 8
Early research (Phase 1)Study completedNCT00052416
What this trial is testing

Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
Beth Israel Deaconess Medical Center
Testing effectiveness (Phase 2)Ended earlyNCT01944943
What this trial is testing

Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
Diffuse Large B-cell LymphomaIndolent Non-hodgkin LymphomaPrimary Central Nervous System Lymphoma+1 more
The Lymphoma Academic Research Organisation 31
Testing effectiveness (Phase 2)Temporarily pausedNCT07098364
What this trial is testing

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+9 more
Fred Hutchinson Cancer Center 33
Testing effectiveness (Phase 2)Study completedNCT05169658
What this trial is testing

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular Lymphoma+5 more
University of Washington 42
Testing effectiveness (Phase 2)Study completedNCT00087425
What this trial is testing

Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
National Institute on Aging (NIA) 48
Early research (Phase 1)Looking for participantsNCT05418088
What this trial is testing

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Prolymphocytic Leukemia+15 more
Sumithira Vasu 54
Early research (Phase 1)Active Not RecruitingNCT07166419
What this trial is testing

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Who this might be right for
Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveRecurrent Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic Leukemia+12 more
Ohio State University Comprehensive Cancer Center
Large-scale testing (Phase 3)UnknownNCT00091676
What this trial is testing

Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma

Who this might be right for
Non-Hodgkins Lymphoma
Biovest International 629
Testing effectiveness (Phase 2)Active Not RecruitingNCT03749018
What this trial is testing

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Aggressive Non-Hodgkin LymphomaAnn Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaAnn Arbor Stage II B-Cell Non-Hodgkin Lymphoma+11 more
David Bond, MD 30
Testing effectiveness (Phase 2)Study completedNCT01206777
What this trial is testing

Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

Who this might be right for
Indolent or Intermediate Grade B-cell Malignancy
Ohio State University Comprehensive Cancer Center 52
Next Page
18
24